Naporafenib + Dacarbazine + Temozolomide + Trametinib
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic NRAS-mutant Melanoma
Conditions
Advanced or Metastatic NRAS-mutant Melanoma
Trial Timeline
Apr 29, 2024 → Dec 1, 2028
NCT ID
NCT06346067About Naporafenib + Dacarbazine + Temozolomide + Trametinib
Naporafenib + Dacarbazine + Temozolomide + Trametinib is a phase 3 stage product being developed by Erasca for Advanced or Metastatic NRAS-mutant Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT06346067. Target conditions include Advanced or Metastatic NRAS-mutant Melanoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06346067 | Phase 3 | Active |
Competing Products
20 competing products in Advanced or Metastatic NRAS-mutant Melanoma